プログラム

オーラルセッション

第4日　5月18日（金）　15:25～15:45　C会場（星雲2）

4C-O2-P-1525　　PDF

Exploring the prostate and urinary glycoproteome for novel prostate cancer biomarkers

(¹USP・ ²MQ・ ³FMUSP・ ⁴USD・ ⁵UFRJ)
^oSakuma, Rebeca¹・ Ortega, Fabio³・ Recuero, Saulo³・ Ashwood, Christopher²・ Hinneburg, Hannes²・ Fernandes, Livia⁴・ Domont, Gilberto⁵・ Nogueira, Fabio⁵・ Larsen, Martin⁴・ Srougi, Miguel³・ Leite, Katia³・ Packer, Nicolle²・ Thaysen-andersen, Morten²・ Palmisano, Giuseppe¹

Prostate cancer (PCa) is the second most common cancer in men worldwide. The low specificity of PSA and the variation associated with PCa tumor sampling are still key challenges for accurate diagnostication and prognostication. In this study, we have used integrated glycomics and glycoproteomics to explore the prostate and urinary glycoproteome from a cohort of PCa and benign hyperplasia (BPH) patients in a search for novel PCa biomarker candidates. Interestingly, the data revealed a panel of 55 differentially regulated urinary glycopeptides that were able to accurately stratify PCa and BPH patients. Equally exciting, another panel of 11 proteins tissue proteins were identified with high discriminating power between early and advanced grades of PCa. In parallel, quantitative glycomics provided unprecedented insight into the N-glycome across the five grades of PCa tissues. Multiple N-glycosylation features showed correlation with the PCa grade including high mannosidic and paucimannosidic glycans as well as bisecting-GlcNAc and highly branched fucosylated and sialylated glycans. Collectively, these integrated glycomics and glycoproteomics studies on prostate tissue and urine from PCa and BPH patients provide insight into the involvement of protein glycosylation in PCa development and progression and have produced a promising panel of candidate biomarkers for PCa diagnosis and prognosis.